Potency Validated COVID-19 SARS-CoV-2 neutralizing antibody,Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GMP-V-2019nCoV-SnAb005

Order information

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)

GMP-V-2019nCoV-SnAb005-1mg

 1mg 5090

GMP-V-2019nCoV-SnAb005-10mg

 10mg 35890

GMP-V-2019nCoV-SnAb005-100mg

 100mg 228090

GMP-V-2019nCoV-SnAb005-xmg

 ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Expression platform Cynomolgus (Non human primate, NHP) IgG1
Isotypes Mammalian (human cell)
Products descriptionAnti-2019-nCoV Spike (Spike RBD domain) Cynomolgus (Non human primate, NHP) monoclonal neutralizing antibody (IgG1):

GMP-V-2019nCoV-SnAb005 is a potency validated COVID-19 SARS-CoV-2 neutralizing antibody.This This antibodies can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in SARS-CoV-2 neutralization potency assay. GeneMedi's validated COVID-19 neutralizing antibodies group including:

GMP-V-2019nCoV-SnAb001(human IgG1),

GMP-V-2019nCoV-SnAb002(human IgM),

GMP-V-2019nCoV-SnAb003(human IGA),

GMP-V-2019nCoV-SnAb004(mouse IgG1),and

GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1).

Bioactivity validationValidated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
PurityPurity: ≥95% （SDS-PAGE）
Applicationpositive control in COVID-19 related vaccines and neutralizing antibodies discovery, also act as a benchmark in SARS-CoV-2 neutralization potency assay.
Predicted Molecular Mass48.9&24.2kDa
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.